Do you have to start tirzepatide at 2.5 mg if you were on a high semaglutide dose?

The Mounjaro and Zepbound labels give 2.5 mg once weekly as the recommended starting dose for all patients. Neither label lists a higher starting dose for people who took semaglutide. The SURPASS-SWITCH trial also started people at 2.5 mg after dulaglutide. Any other plan is a prescriber decision outside the label.

Is there a dose conversion chart between Ozempic and Mounjaro?

No FDA label publishes one, and we did not find one in a peer-reviewed primary source. Charts found online are not from the labels. The two drugs are different molecules with different targets, so milligram doses do not translate directly.

How long does semaglutide stay in your body after the last dose?

The Ozempic label says semaglutide has a half-life of about 1 week and stays in the circulation for about 5 weeks after the last dose. The Wegovy label gives about 5 to 7 weeks for its higher doses. This means some semaglutide is still present when tirzepatide starts.

Will you lose more weight after a switch to tirzepatide?

It is not certain. In SURMOUNT-5, people who started tirzepatide lost 20.2% of body weight on average and people who started semaglutide lost 13.7% at 72 weeks. That trial did not study people who switched, and the semaglutide switch studies are small.

Can you switch back to semaglutide if tirzepatide does not suit you?

The labels do not give instructions for that direction either. Each drug's label has its own starting dose and escalation schedule. Your prescriber decides the plan based on your side effects and your response.

How Do You Switch From Semaglutide to Tirzepatide Safely?

The short answer: No FDA label gives step-by-step instructions for moving from semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro, Zepbound). The tirzepatide labels give one starting dose for everyone: 2.5 mg once weekly, raised in 2.5 mg steps after at least 4 weeks on each dose. The Zepbound label also says not to use it together with any GLP-1 receptor agonist. The timing of the first tirzepatide dose and how fast to escalate are your prescriber's decisions.

What do the FDA labels say about switching?

The labels do not address switching from semaglutide. Neither the Mounjaro label nor the Zepbound label has a section on patients who come from another GLP-1 drug. Both give the same starting point for every patient.

Starting dose: 2.5 mg injected under the skin once weekly. The Zepbound label says this dose is for treatment initiation and is not approved as a maintenance dose.
Escalation: After 4 weeks, Zepbound goes to 5 mg once weekly. Both labels then allow increases in 2.5 mg steps after at least 4 weeks on the current dose.
Maximum: 15 mg once weekly in adults.

The labels state the reason for this schedule: it reduces the risk of gastrointestinal side effects. Neither label lists a higher starting dose for a person who already tolerated semaglutide. No label publishes a dose-equivalence chart between the two drugs, and we did not find one in a primary source.

Can you take semaglutide and tirzepatide at the same time?

The Zepbound label says no. Under its limitations of use, it states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Semaglutide is a GLP-1 receptor agonist, so the two drugs are not meant to overlap as ongoing treatment.

The current Mounjaro label on DailyMed does not carry the same sentence. That does not make the combination a studied or approved one. Tirzepatide already acts on the GLP-1 receptor (and on the GIP receptor), so a second GLP-1 drug adds overlap, not a new mechanism. A switch means you stop one drug and start the other.

When do you take the first tirzepatide dose after the last semaglutide dose?

No label and no published trial we found sets a rule for this. It is the prescriber's decision. Three label facts explain what the prescriber weighs.

Both drugs are dosed once weekly.
The Ozempic label says semaglutide has an elimination half-life of about 1 week and stays in the circulation for about 5 weeks after the last dose. The Wegovy label gives about 5 to 7 weeks for its higher doses.
The tirzepatide labels give tirzepatide a half-life of about 5 days.

So semaglutide is still in your body when the first tirzepatide dose goes in, whatever day is chosen. The labels do not say whether that carryover changes side effects. The Wegovy label has one switching rule, but it covers a move from Wegovy injection to Wegovy tablets, not a move to tirzepatide. Do not apply it to a different drug on your own.

If you miss a dose during the change, the label rules for each drug still apply. Our guide to missed GLP-1 doses covers them.

Is there research on switching to tirzepatide?

There is one randomized switching trial, and it did not involve semaglutide. SURPASS-SWITCH, published in Annals of Internal Medicine in 2025, enrolled 282 adults with type 2 diabetes who took dulaglutide (Trulicity) 0.75 mg or 1.5 mg. Half switched to tirzepatide. Half raised their dulaglutide dose.

At week 40, HbA1c fell 1.44% with tirzepatide and 0.67% with dulaglutide. Weight fell 10.5 kg with tirzepatide and 3.6 kg with dulaglutide. Serious adverse events were reported by 7.2% and 7.0% of participants. The most common side effects were nausea and diarrhea. The trial record shows that the tirzepatide group started at 2.5 mg and went up by 2.5 mg every 4 weeks. That matches the label schedule. Eli Lilly funded the trial, and it was open-label.

For semaglutide specifically, the published evidence is small and retrospective.

A Japanese study followed 15 people with type 2 diabetes who switched from semaglutide 1.0 mg because of inadequate weight loss. All started tirzepatide at 2.5 mg. The authors wrote that the best tirzepatide dose after such a switch remains unclear.
A US case series of 10 patients with type 2 diabetes reported lower HbA1c and weight after a switch from a GLP-1 drug, with few adverse events. Its authors noted a lack of data on how to switch between the two classes.

We did not find a randomized trial that tests a semaglutide-to-tirzepatide switch protocol. Studies this small cannot prove that one switching method is safer than another.

What side effects should you expect when you restart dose escalation?

Expect the same stomach and bowel effects you may remember from your first weeks on semaglutide. In the Zepbound weight-reduction trials, nausea affected 25% to 29% of people on tirzepatide and 8% on placebo. Diarrhea affected 19% to 23%, and vomiting 8% to 13%. The label says most of these events happened during dose escalation and decreased over time.

Previous semaglutide use is not proven to protect you. The labels do not say that it does. In SURPASS-SWITCH, people who already took a GLP-1 drug still reported nausea and diarrhea most often after the switch. See our GLP-1 side effects guide for the full list and the warning signs.

Two label points are easy to miss during a switch.

Birth control pills: Tirzepatide delays stomach emptying, most after the first dose. Both labels advise people on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after the start and for 4 weeks after each dose increase.
Severe symptoms: Severe or persistent abdominal pain can be a sign of pancreatitis. The labels say to stop the drug if pancreatitis is suspected. Contact your prescriber quickly.

Does switching raise the risk of low blood sugar?

It can if you also take insulin or a sulfonylurea such as glipizide or glimepiride. The Mounjaro label warns that this combination may increase the risk of hypoglycemia, including severe hypoglycemia. In one adult trial with a sulfonylurea, blood glucose below 54 mg/dL occurred in 9.9% to 13.8% of people on Mounjaro.

The Zepbound label reports a similar pattern in people with type 2 diabetes. Hypoglycemia occurred in 10.3% of those who also took a sulfonylurea and 2.1% of those who did not. Both labels tell prescribers to consider a lower dose of insulin or the sulfonylurea when tirzepatide starts. That is a prescriber decision. Do not change insulin doses on your own.

The mounjaro.md site covers tirzepatide for diabetes in more detail.

Why do people switch from semaglutide to tirzepatide?

The most common reason in the published studies is a smaller response than hoped for. The Japanese semaglutide study and the US case series both enrolled people who needed more weight loss or better glucose control.

Head-to-head data support that reasoning for weight. In SURMOUNT-5, 751 adults with obesity but without type 2 diabetes took the maximum tolerated dose of either drug for 72 weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. The trial was open-label and funded by Eli Lilly. It compared people who started each drug fresh. It did not test people who switched, so it cannot predict your result after a switch.

Other reasons include side effects, insurance coverage, cost, and supply. Our Ozempic and Mounjaro comparison explains how the two drugs differ.

The bottom line

No FDA label tells you how to switch from semaglutide to tirzepatide. The tirzepatide labels start every patient at 2.5 mg once weekly and raise the dose in 2.5 mg steps at least 4 weeks apart. The Zepbound label says not to combine it with a GLP-1 receptor agonist. The one randomized switching trial used the label schedule after dulaglutide, not semaglutide. Timing of the first dose is your prescriber's decision. Ask about your insulin or sulfonylurea dose and about birth control before the first injection.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Do not stop, start, or change a GLP-1 medication without your prescriber.